Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Common Equity: 2009-2024

Historic Common Equity for Heron Therapeutics (HRTX) over the last 13 years, with Dec 2024 value amounting to -$33.7 million.

  • Heron Therapeutics' Common Equity rose 137.21% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 137.21%. This contributed to the annual value of -$33.7 million for FY2024, which is 0.95% up from last year.
  • As of FY2024, Heron Therapeutics' Common Equity stood at -$33.7 million, which was up 0.95% from -$34.0 million recorded in FY2023.
  • Over the past 5 years, Heron Therapeutics' Common Equity peaked at $236.5 million during FY2020, and registered a low of -$34.0 million during FY2023.
  • In the last 3 years, Heron Therapeutics' Common Equity had a median value of -$33.7 million in 2024 and averaged -$18.0 million.
  • As far as peak fluctuations go, Heron Therapeutics' Common Equity slumped by 350.32% in 2023, and later increased by 0.95% in 2024.
  • Over the past 5 years, Heron Therapeutics' Common Equity (Yearly) stood at $236.5 million in 2020, then tumbled by 67.20% to $77.6 million in 2021, then plummeted by 82.50% to $13.6 million in 2022, then slumped by 350.32% to -$34.0 million in 2023, then increased by 0.95% to -$33.7 million in 2024.